Cyclacel Pharmaceuticals Inc (CYCC)

4.17
0.14 3.20
NASDAQ : Health Care
Prev Close 4.31
Open 4.20
Day Low/High 4.09 / 4.34
52 Wk Low/High 3.60 / 12.60
Volume 54.84K
Avg Volume 146.00K
Exchange NASDAQ
Shares Outstanding 4.25M
Market Cap 17.26M
EPS -5.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Cyclacel Pharmaceuticals Reports 3rd Quarter 2016 Financial Results

Cyclacel Pharmaceuticals Reports 3rd Quarter 2016 Financial Results

Conference Call Scheduled for November 14, 2016 at 4:30 p.m. ET

Cyclacel Pharmaceuticals's Preferred Stock Shares Cross 9% Yield Mark

Cyclacel Pharmaceuticals's Preferred Stock Shares Cross 9% Yield Mark

In trading on Tuesday, shares of Cyclacel Pharmaceuticals, Inc's 6% Convertible Exchangeable Preferred Stock were yielding above the 9% mark based on its quarterly dividend (annualized to $0.60), with shares changing hands as low as $6.51 on the day. This compares to an average yield of 10.90% in the "Biotechnology" preferred stock category, according to Preferred Stock Channel.

Cyclacel's CYC065 Demonstrates Promising Activity In MYCN-Addicted Neuroblastoma In Preclinical Data Presented At Childhood Cancer 2016

Cyclacel's CYC065 Demonstrates Promising Activity In MYCN-Addicted Neuroblastoma In Preclinical Data Presented At Childhood Cancer 2016

Data support CYC065 as potential treatment for MYCN amplified/overexpressed neuroblastoma

Cyclacel Stock Runs on Momentum Rocket Fueled by 'Dumb & Dumber' Optimism

Cyclacel Stock Runs on Momentum Rocket Fueled by 'Dumb & Dumber' Optimism

Shares of biotech micro-cap Cyclacel Pharmaceuticals have doubled in price in the past 10 days. Call it the Lloyd Christmas effect.

Here's Why Cyclacel Pharmaceuticals (CYCC) Stock Is Surging Today

Here's Why Cyclacel Pharmaceuticals (CYCC) Stock Is Surging Today

Cyclacel Pharmaceuticals (CYCC) stock is soaring on Monday afternoon as Tang Capital revealed a passive stake in the company.

Cyclacel Pharmaceuticals (CYCC) Stock Pops, H.C. Wainwright Bullish

Cyclacel Pharmaceuticals (CYCC) Stock Pops, H.C. Wainwright Bullish

H.C. Wainwright analysts are bullish on Cyclacel Pharmaceuticals (CYCC) ahead of the company's acute myeloid leukemia study results.

Cyclacel Pharmaceuticals Reports 2nd Quarter 2016 Financial Results

Cyclacel Pharmaceuticals Reports 2nd Quarter 2016 Financial Results

Conference Call Scheduled August 10, 2016 at 4:30 p.m. EDT

Cyclacel Reports Updated Data From Its DNA Damage Response Program On Seliciclib And Sapacitabine Combination In Patients With Solid Tumors At ASCO

Cyclacel Reports Updated Data From Its DNA Damage Response Program On Seliciclib And Sapacitabine Combination In Patients With Solid Tumors At ASCO

Combination Showed 35.6% Disease Control Rate and Durable Responses including CR and PR in Heavily-Pretreated Patients with BRCA Mutations

Cyclacel Announces Reverse Stock Split

Cyclacel Announces Reverse Stock Split

Cyclacel Pharmaceuticals Reports First Quarter 2016 Financial Results

Cyclacel Pharmaceuticals Reports First Quarter 2016 Financial Results

Conference Call Scheduled May 11, 2016 at 4:30 p.m. EDT

Cyclacel Pharmaceuticals Reports Fourth Quarter And Full Year 2015 Financial Results

Cyclacel Pharmaceuticals Reports Fourth Quarter And Full Year 2015 Financial Results

-- Conference Call Scheduled March 24, 2016 at 4:30 p.m. EDT --

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Involving Possible Breaches Of Fiduciary Duty By The Board Of Cyclacel Pharmaceuticals, Inc.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Involving Possible Breaches Of Fiduciary Duty By The Board Of Cyclacel Pharmaceuticals, Inc.

Levi & Korsinsky announces it has commenced an investigation of Cyclacel Pharmaceuticals, Inc.

Cyclacel Reviews 2015 Achievements And Announces Key Business Objectives For 2016

Cyclacel Reviews 2015 Achievements And Announces Key Business Objectives For 2016

Company to Present at the Biotech Showcase(TM) 2016 Conference

CYC065, Cyclacel's Novel CDK2/9 Inhibitor, Prolongs Survival In MYCN-Addicted Neuroblastoma Models

CYC065, Cyclacel's Novel CDK2/9 Inhibitor, Prolongs Survival In MYCN-Addicted Neuroblastoma Models

In Vitro and In Vivo Preclinical Data to be Presented at the Neuroblastoma UK Annual Meeting

Cyclacel Pharmaceuticals Reports Third Quarter 2015 Financial Results

Cyclacel Pharmaceuticals Reports Third Quarter 2015 Financial Results

Conference Call Scheduled November 12, 2015 at 4:30 p.m. EST